AR082073A1 - Compuesto del acido aril-pirazol-carboxilico y su uso para preparar un medicamento util para disminuir la secrecion de citocinas desde un macrofago y enfermedades o condiciones mediadas por dp1, fp, ep1, tp y/o ep4 - Google Patents
Compuesto del acido aril-pirazol-carboxilico y su uso para preparar un medicamento util para disminuir la secrecion de citocinas desde un macrofago y enfermedades o condiciones mediadas por dp1, fp, ep1, tp y/o ep4Info
- Publication number
- AR082073A1 AR082073A1 ARP110102369A ARP110102369A AR082073A1 AR 082073 A1 AR082073 A1 AR 082073A1 AR P110102369 A ARP110102369 A AR P110102369A AR P110102369 A ARP110102369 A AR P110102369A AR 082073 A1 AR082073 A1 AR 082073A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- group
- substituted
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
Abstract
Compuesto del ácido aril-pirazol-carboxílico, que es 1-[(2-{[(alquilo o arilo)metilo]oxi}halo o haloalquilo sustituido-fenilo)alquilo]-5-hidrocarbilo o ácido hidrocarbilo-1H-carboxílico pirazol o ácido alquilenilcarboxílico sustituido o un hidrocarbilo o un hidrocarbilo sulfonamida sustituido de dicho ácido carboxílico o dicho ácido alquilenilcarboxílico, siempre que dicho compuesto no sea ácido 3-carboxílico, una sulfonamida del mismo o ácido 3-metilenilcarboxílico o un compuesto de fórmula (1) en la que R1 se selecciona del grupo formado por OR7, N(R7)2, y N(R7)SO2R7 en el que R7 se selecciona del grupo formado por H, alquilo y arilo, en el que dicho alquilo y arilo puede ser sustituido con flúor; R2 es seleccionado del grupo formado por H y alquilo; R3 es seleccionado del grupo formado por H y alquilo; en el que R2 y R3, individualmente o conjuntamente pueden formar un anillo cicloalquilo; X es (CH2)n en el que n es 0 o un entero que oscila desde 1 a 3; siempre que cuando n es 0 ó 1, R1 no sea OR7 o NR2; R4 se selecciona del grupo formado por H, alquilo y fluoroalquilo; R5 se selecciona del grupo formado por H, hidroxi, alquilo, arilo, alcoxi, ariloxi, halógeno, nitro, amino, ciano e hidroxi, halógeno, nitro, amino y ciano-sustituido alquilo, arilo, alcoxi o ariloxi; R6 se selecciona del grupo formado por H, hidroxi, alquilo, arilo, alcoxi, ariloxi. halógeno, nitro, amino, ciano e hidroxi, halógeno, nitro, amino y ciano-alquilo sustituido, arilo, alcoxi y ariloxi; Z es (CH2)m en el que m es 0 o un entero que oscila entre 1 a 3; Y es seleccionado del grupo formado por O, S, SO, SO2 y (CH2)p, en el que p es 0 o un entero que oscila entre 1 a 3; y W se selecciona del grupo formado por alquilo y arilo. Su uso para preparar un medicamento útil para disminuir la secreción de citocinas desde un macrófago, enfermedades o condiciones mediadas por DP1, FP, EP1, TP y/o EP4, enfermedades inflamatorias por infiltración monolítica, uveítis y conjuntivitis alérgica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36075510P | 2010-07-01 | 2010-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082073A1 true AR082073A1 (es) | 2012-11-07 |
Family
ID=44514984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102369A AR082073A1 (es) | 2010-07-01 | 2011-07-01 | Compuesto del acido aril-pirazol-carboxilico y su uso para preparar un medicamento util para disminuir la secrecion de citocinas desde un macrofago y enfermedades o condiciones mediadas por dp1, fp, ep1, tp y/o ep4 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8492424B2 (es) |
| EP (1) | EP2588459B1 (es) |
| JP (1) | JP5922116B2 (es) |
| KR (1) | KR20130141434A (es) |
| CN (1) | CN103038219B (es) |
| AR (1) | AR082073A1 (es) |
| AU (1) | AU2011272716B2 (es) |
| BR (1) | BR112013000065A2 (es) |
| CA (1) | CA2804194C (es) |
| CL (1) | CL2013000002A1 (es) |
| CO (1) | CO6680625A2 (es) |
| ES (1) | ES2625355T3 (es) |
| MX (1) | MX2013000170A (es) |
| RU (1) | RU2013102967A (es) |
| SG (1) | SG186886A1 (es) |
| TW (1) | TW201206891A (es) |
| WO (1) | WO2012003414A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8859606B2 (en) | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| JP6132851B2 (ja) * | 2011-12-21 | 2017-05-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物 |
| AU2012362579B2 (en) | 2011-12-27 | 2017-08-31 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2013101598A1 (en) * | 2011-12-27 | 2013-07-04 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| ES2708624T3 (es) | 2012-08-15 | 2019-04-10 | Univ Virginia Patent Foundation | Composiciones y métodos para tratar la enfermedad arterial periférica |
| CN105008331B (zh) * | 2013-01-21 | 2018-02-16 | 阿勒根公司 | 作用于多个前列腺素受体、产生一般抗炎反应的化合物 |
| WO2015066541A1 (en) | 2013-10-31 | 2015-05-07 | Allergan, Inc. | 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1h-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof |
| CN106146400A (zh) * | 2015-03-20 | 2016-11-23 | 四川大学 | 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途 |
| US10462745B2 (en) | 2016-01-15 | 2019-10-29 | Google Llc | Systems and methods for extending battery life by monitoring device activity |
| CN107723304A (zh) * | 2016-08-10 | 2018-02-23 | 中国科学院上海生命科学研究院 | Prkar2a在炎症消退中的应用 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7273883B2 (en) | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| WO2004103970A1 (en) * | 2003-05-20 | 2004-12-02 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| ATE386725T1 (de) * | 2003-10-24 | 2008-03-15 | Glaxo Group Ltd | Heterocyclylverbindungen |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
-
2011
- 2011-06-28 US US13/170,467 patent/US8492424B2/en active Active
- 2011-07-01 WO PCT/US2011/042729 patent/WO2012003414A1/en active Application Filing
- 2011-07-01 SG SG2013000054A patent/SG186886A1/en unknown
- 2011-07-01 RU RU2013102967/04A patent/RU2013102967A/ru not_active Application Discontinuation
- 2011-07-01 MX MX2013000170A patent/MX2013000170A/es active IP Right Grant
- 2011-07-01 US US13/808,020 patent/US20140121258A1/en not_active Abandoned
- 2011-07-01 AR ARP110102369A patent/AR082073A1/es unknown
- 2011-07-01 TW TW100123408A patent/TW201206891A/zh unknown
- 2011-07-01 CN CN201180038338.0A patent/CN103038219B/zh active Active
- 2011-07-01 EP EP11734222.0A patent/EP2588459B1/en active Active
- 2011-07-01 JP JP2013518748A patent/JP5922116B2/ja active Active
- 2011-07-01 BR BR112013000065A patent/BR112013000065A2/pt not_active IP Right Cessation
- 2011-07-01 AU AU2011272716A patent/AU2011272716B2/en active Active
- 2011-07-01 KR KR1020137002639A patent/KR20130141434A/ko not_active Application Discontinuation
- 2011-07-01 ES ES11734222.0T patent/ES2625355T3/es active Active
- 2011-07-01 CA CA2804194A patent/CA2804194C/en active Active
-
2013
- 2013-01-02 CL CL2013000002A patent/CL2013000002A1/es unknown
- 2013-01-29 CO CO13016511A patent/CO6680625A2/es unknown
- 2013-05-20 US US13/898,254 patent/US20130253028A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103038219B (zh) | 2016-08-24 |
| US20120165382A1 (en) | 2012-06-28 |
| CO6680625A2 (es) | 2013-05-31 |
| US8492424B2 (en) | 2013-07-23 |
| RU2013102967A (ru) | 2014-08-10 |
| SG186886A1 (en) | 2013-02-28 |
| CA2804194A1 (en) | 2012-01-05 |
| KR20130141434A (ko) | 2013-12-26 |
| TW201206891A (en) | 2012-02-16 |
| US20140121258A1 (en) | 2014-05-01 |
| ES2625355T3 (es) | 2017-07-19 |
| MX2013000170A (es) | 2013-05-28 |
| CA2804194C (en) | 2019-03-05 |
| CL2013000002A1 (es) | 2013-05-31 |
| US20130253028A1 (en) | 2013-09-26 |
| EP2588459B1 (en) | 2017-03-01 |
| WO2012003414A1 (en) | 2012-01-05 |
| AU2011272716A1 (en) | 2013-02-07 |
| JP2013535424A (ja) | 2013-09-12 |
| AU2011272716B2 (en) | 2016-05-19 |
| BR112013000065A2 (pt) | 2019-09-24 |
| EP2588459A1 (en) | 2013-05-08 |
| JP5922116B2 (ja) | 2016-05-24 |
| CN103038219A (zh) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082073A1 (es) | Compuesto del acido aril-pirazol-carboxilico y su uso para preparar un medicamento util para disminuir la secrecion de citocinas desde un macrofago y enfermedades o condiciones mediadas por dp1, fp, ep1, tp y/o ep4 | |
| ES2570784T3 (es) | Piridinas sustituidas como bloqueadores de los canales de sodio | |
| AR070268A1 (es) | Compuesto de oxa-azaspiro, su uso para la fabricacion de un medicamento para la modulacion de receptores y5 de npy y composicion farmaceutica que lo comprende | |
| PE20091407A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2 | |
| PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
| RS54527B1 (en) | DEGREE DERIVATIVES OF 3-PHENYL-PROPIONIC ACIDS AND THEIR USE | |
| ES2599728T3 (es) | Derivados de isoxazolina usados en el control de ectoparásitos | |
| PE20081505A1 (es) | Inhibidores de serina palmitoiltransferasa | |
| AR085678A1 (es) | Amidas de acido n-(1,2,5-oxadiazol-3-il)-, n-(tetrazol-5-il)- y n-(triazol-5-il)bicicloaril-carboxilico y su uso como herbicidas | |
| PE20120911A1 (es) | Derivados de prolina como inhibidores de catepsina | |
| RS53395B (en) | DERIVATIVES N1-SULFONIL-5-FLUORPIRIMIDINONA | |
| MA34006B1 (fr) | Derives de dihydrofurane utilises comme composes insecticides | |
| TNSN08372A1 (en) | Heterocyclic amides for use as pharmaceuticals | |
| RS52042B (en) | FUNGICID MIXTURES | |
| PE20141056A1 (es) | Metodos para el tratamiento de vhc | |
| AR092390A1 (es) | Nucleosidos ramificados en 2 para el tratamiento de infecciones virales | |
| RS54563B1 (en) | GLYCOSIDE DERIVATIVES AND THEIR USE | |
| PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
| RS52261B (en) | AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR | |
| PE20080855A1 (es) | Derivados de pirazina-2-carboxamida | |
| CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| AR076841A1 (es) | Derivados de triazol-sustituidos, procesos para su preparacion y metodos de uso en el control de plagas | |
| AR065119A1 (es) | Compuesto de 2- oxo-1-oxa-3-azaespiro (4,5) decan-3-ilo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |